ANI Pharmaceuticals, Inc. (ANIP) Key Metrics
ANIP valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.66B
- Enterprise value
- $1.94B
- P/E (TTM)
- 15.6 10-yr median 53.4
- Forward P/E
- 7.1
- PEG ratio
- 1.06
- Price / sales
- 1.7 10-yr median 2.3
- Price / book
- 2.9 10-yr median 2.6
- EV / EBITDA
- 7.9 10-yr median 15.1
- Dividend yield
- —
- Beta
- 0.49
ANIP key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsANIP valuation Price multiples at each fiscal year-end price.
ANIP returns How much profit the business earns on the capital it uses.
ANIP per-share figures Results divided by the shares outstanding at year-end.
ANIP financial health Debt, liquidity and how easily interest is covered.
ANIP efficiency & capital use Working capital cycle and where the cash goes.
ANIP valuation history
ANIP returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ANIP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ANIP cash returned to shareholders
ANIP price vs earnings per share
ANIP key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.68B | $1.07B | $1.00B | $654.1M | $580.4M | $347.4M | $742.5M | $530.0M | $744.2M | $701.6M |
| Enterprise value | $1.72B | $1.54B | $1.07B | $892.4M | $767.5M | $525.3M | $865.9M | $670.0M | $914.6M | $794.8M |
| P/E ratio | 21.4 | — | 53.4 | — | — | — | 121.8 | 34.2 | — | 178.3 |
| Price / sales | 1.9 | 1.7 | 2.1 | 2.1 | 2.7 | 1.7 | 3.6 | 2.6 | 4.2 | 5.5 |
| Price / book | 3.1 | 2.5 | 2.2 | 1.9 | 1.6 | 1.8 | 3.5 | 2.7 | 4.3 | 4.1 |
| Price / free cash flow | 11.1 | 22.7 | 10.0 | — | — | — | 41.1 | 9.4 | — | — |
| Price / operating cash flow | 9.0 | 16.7 | 8.4 | — | 174.7 | 22.8 | 16.3 | 7.9 | 18.9 | 25.5 |
| EV / sales | 1.9 | 2.5 | 2.2 | 2.8 | 3.6 | 2.5 | 4.2 | 3.3 | 5.2 | 6.2 |
| EV / EBITDA | 8.3 | 24.4 | 10.0 | 35.6 | 246.3 | 18.7 | 14.3 | 9.7 | 16.0 | 14.1 |
| EV / free cash flow | 11.4 | 32.7 | 10.6 | — | — | — | 47.9 | 11.9 | — | — |
| Earnings yield | 4.7% | −1.7% | 1.9% | −7.3% | −7.3% | −6.5% | 0.8% | 2.9% | −0.1% | 0.6% |
| Free cash flow yield | 9.0% | 4.4% | 10.0% | −7.3% | −3.5% | −15.3% | 2.4% | 10.6% | −9.2% | −17.3% |
| Dividend yield | 0.1% | 0.2% | 0.2% | 0.2% | 0.0% | 0.2% | 0.8% | 0.0% | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 0.8% | 1.2% | 0.7% | 0.5% | 0.2% | 0.6% | 0.9% | 0.2% | 0.0% | 0.4% |
| Share price at fiscal year-end | $78.94 | $55.28 | $55.14 | $40.23 | $46.08 | $29.04 | $61.67 | $45.02 | $64.45 | $60.62 |
| Per share | ||||||||||
| Revenue per share | $41.61 | $31.80 | $26.76 | $19.46 | $17.16 | $17.43 | $17.16 | $17.12 | $15.31 | $11.11 |
| Earnings per share | $3.69 | −$0.96 | $1.03 | −$2.95 | −$3.38 | −$1.88 | $0.51 | $1.32 | −$0.09 | $0.34 |
| Operating cash flow per share | $8.73 | $3.31 | $6.54 | −$1.92 | $0.26 | $1.28 | $3.79 | $5.70 | $3.41 | $2.37 |
| Free cash flow per share | $7.11 | $2.44 | $5.52 | −$2.93 | −$1.61 | −$4.43 | $1.50 | $4.77 | −$5.94 | −$10.51 |
| Cash per share | $13.45 | $7.83 | $12.15 | $2.97 | $7.96 | $0.66 | $5.18 | $3.65 | $2.70 | $2.36 |
| Book value per share | $25.47 | $22.18 | $25.15 | $20.82 | $28.48 | $16.36 | $17.67 | $16.76 | $15.13 | $14.66 |
| Tangible book value per share | −$0.06 | −$8.97 | $12.11 | $3.61 | $2.92 | $0.30 | $2.39 | −$0.67 | −$4.93 | −$0.69 |
| Dividends per share | $0.05 | $0.08 | $0.09 | $0.10 | $0.02 | $0.05 | $0.48 | $0.02 | $0.00 | $0.00 |
| Capex per share | $1.62 | $0.88 | $1.02 | $1.01 | $1.88 | $5.71 | $2.29 | $0.93 | $9.35 | $12.88 |
| Debt per share | $15.32 | $32.31 | $15.70 | $17.62 | $22.81 | $15.52 | $15.43 | $15.55 | $17.45 | $10.42 |
| Shares outstanding | 21.2M | 19.3M | 18.2M | 16.3M | 12.6M | 12.0M | 12.0M | 11.8M | 11.5M | 11.6M |
| Change in shares outstanding | +9.9% | +6.2% | +11.9% | +29.1% | +5.3% | −0.6% | +2.3% | +1.9% | −0.2% | +0.1% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 16.2% | −4.2% | 4.7% | −13.7% | −15.4% | −11.0% | 3.0% | 8.3% | −0.6% | 2.4% |
| Return on invested capital (ROIC) | 9.0% | 0.1% | 8.1% | −5.0% | −6.8% | −3.6% | 4.9% | 8.0% | 4.7% | 5.3% |
| Return on assets (ROA) | 5.8% | −1.7% | 2.3% | −6.3% | −6.9% | −4.9% | 1.4% | 3.7% | −0.3% | 1.3% |
| Return on tangible assets | 8.7% | −2.7% | 2.8% | −10.0% | −9.5% | −8.4% | 2.2% | 6.9% | −0.6% | 2.7% |
| Free cash flow margin | 17.1% | 7.7% | 20.6% | −15.1% | −9.4% | −25.4% | 8.8% | 27.9% | −38.8% | −94.5% |
| Income quality (OCF / net income) | 2.36 | — | 6.33 | — | — | — | 7.49 | 4.33 | — | 6.98 |
| Financial health | ||||||||||
| Total debt | $325.2M | $624.1M | $285.7M | $286.5M | $287.4M | $185.7M | $185.7M | $183.0M | $201.5M | $120.6M |
| Cash & short-term investments | $285.6M | $151.2M | $221.1M | $48.2M | $100.3M | $7.9M | $62.3M | $43.0M | $31.1M | $27.4M |
| Net debt | $39.6M | $472.9M | $64.5M | $238.3M | $187.1M | $177.8M | $123.4M | $140.0M | $170.4M | $93.3M |
| Debt / equity | 0.60 | 1.46 | 0.62 | 0.85 | 0.80 | 0.95 | 0.87 | 0.93 | 1.15 | 0.71 |
| Debt / assets | 0.23 | 0.49 | 0.32 | 0.38 | 0.37 | 0.40 | 0.41 | 0.43 | 0.49 | 0.37 |
| Net debt / EBITDA | 0.19 | 7.49 | 0.61 | 9.52 | 60.04 | 6.32 | 2.03 | 2.03 | 2.98 | 1.66 |
| Current ratio | 2.71 | 2.72 | 3.57 | 3.46 | 3.68 | 2.17 | 3.04 | 0.92 | 3.35 | 3.22 |
| Quick ratio | 2.19 | 2.02 | 2.81 | 2.40 | 2.74 | 1.39 | 2.26 | 0.68 | 2.39 | 2.40 |
| Interest coverage | 4.0 | 0.0 | 1.7 | -1.3 | -3.3 | -1.7 | 1.3 | 2.4 | 2.4 | 1.8 |
| Working capital | $475.0M | $334.0M | $374.3M | $244.8M | $234.2M | $91.8M | $126.0M | −$12.7M | $92.4M | $71.1M |
| Invested capital | $580.3M | $901.5M | $522.1M | $576.8M | $545.8M | $373.5M | $336.2M | $337.3M | $345.1M | $262.9M |
| Tangible asset value | −$1.3M | −$173.3M | $220.4M | $58.7M | $36.7M | $3.6M | $28.8M | −$7.9M | −$56.9M | −$8.0M |
| Net current asset value | −$146.5M | −$327.5M | $73.0M | −$77.3M | −$91.1M | −$95.2M | −$56.3M | −$80.5M | −$105.8M | −$50.2M |
| Graham number | $45.99 | — | $24.17 | — | — | — | $14.19 | $22.28 | — | $10.59 |
| Graham net-net per share | −$15.63 | −$24.29 | −$2.67 | −$12.09 | −$13.92 | −$12.99 | −$8.60 | −$10.32 | −$12.41 | −$6.77 |
| Capital allocation | ||||||||||
| Dividends paid | $1.2M | $1.6M | $1.6M | $1.6M | $190,000 | $618,000 | $5.7M | $190,000 | $0 | $0 |
| Share buybacks (net) | $12.2M | $11.0M | $5.0M | $2.0M | $890,000 | $1.5M | $1.0M | $659,000 | $259,000 | $2.6M |
| Dividend payout ratio | 1.5% | — | 8.7% | — | — | — | 94.2% | 1.2% | — | 0.0% |
| Dividends + buybacks / free cash flow | 8.9% | 26.7% | 6.6% | — | — | — | 37.4% | 1.5% | — | — |
| Capex / revenue | 3.9% | 2.8% | 3.8% | 5.2% | 10.9% | 32.8% | 13.3% | 5.4% | 61.1% | 115.9% |
| Capex / operating cash flow | 18.5% | 26.5% | 15.6% | — | 711.6% | 447.5% | 60.4% | 16.3% | 274.0% | 542.6% |
| Capex / depreciation | 0.38 | 0.25 | 0.31 | 0.28 | 0.50 | 1.53 | 0.62 | 0.32 | 3.87 | 6.67 |
| Stock-based compensation / revenue | 4.3% | 4.8% | 4.2% | 4.6% | 4.9% | 6.2% | 4.5% | 3.4% | 3.4% | 4.7% |
| R&D / revenue | 5.8% | 7.3% | 7.0% | 7.1% | 5.3% | 7.7% | 9.6% | 7.6% | 5.1% | 2.3% |
| SG&A / revenue | 36.0% | 40.6% | 30.9% | 40.4% | 39.0% | 31.2% | 27.0% | 21.9% | 17.9% | 21.6% |
| Efficiency | ||||||||||
| Days sales outstanding | 103.9 | 114.0 | 122.8 | 169.6 | 189.4 | 147.0 | 121.0 | 111.9 | 108.0 | 96.2 |
| Days of inventory on hand | 118.0 | 180.9 | 217.7 | 246.0 | 258.5 | 228.2 | 256.2 | 195.5 | 147.6 | 148.0 |
| Days payables outstanding | 45.6 | 60.1 | 66.3 | 68.7 | 62.1 | 54.2 | 67.9 | 31.3 | 16.2 | 20.4 |
| Cash conversion cycle (days) | 176.3 | 234.8 | 274.2 | 346.8 | 385.8 | 321.0 | 309.4 | 276.2 | 239.4 | 223.9 |
| Receivables turnover | 3.51 | 3.20 | 2.97 | 2.15 | 1.93 | 2.48 | 3.02 | 3.26 | 3.38 | 3.79 |
| Payables turnover | 8.00 | 6.08 | 5.50 | 5.31 | 5.88 | 6.74 | 5.38 | 11.67 | 22.52 | 17.88 |
| Inventory turnover | 3.09 | 2.02 | 1.68 | 1.48 | 1.41 | 1.60 | 1.42 | 1.87 | 2.47 | 2.47 |
| Asset turnover | 0.65 | 0.56 | 0.58 | 0.41 | 0.35 | 0.45 | 0.47 | 0.48 | 0.48 | 0.42 |
| Average receivables | $251.4M | $191.9M | $163.8M | $147.0M | $112.2M | $84.0M | $68.5M | $61.8M | $52.3M | $33.9M |
| Average payables | $54.1M | $41.2M | $33.0M | $26.1M | $17.1M | $12.9M | $11.7M | $6.3M | $3.5M | $2.7M |
| Average inventory | $139.9M | $124.0M | $108.3M | $93.5M | $71.2M | $54.5M | $44.3M | $39.1M | $32.0M | $19.8M |
| Intangibles / total assets | 37.6% | 46.9% | 26.2% | 36.8% | 41.7% | 41.7% | 40.3% | 47.7% | 56.2% | 55.0% |
Computed from ANIP's annual financial statements (latest annual report filed February 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ANIP valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), ANI Pharmaceuticals traded at 21.4 times earnings, against a 10-year median of 53.4. Based on the latest twelve months, the trailing P/E is 15.6 and the forward P/E is 7.1. ANI Pharmaceuticals earned a return on equity of 16.2% and a return on invested capital of 9.0% in fiscal 2025. It ended the year with $325.2 million of debt and $285.6 million in cash and short-term investments, net debt of $39.6 million. It returned $13.4 million to shareholders: $1.2 million in dividends and $12.2 million in share buybacks, 9% of free cash flow. The share count rose 83.4% from 11.6M to 21.2M over 9 years.
See the ANIP income statement, the ANIP chart for price history, or the ANIP stock overview for the latest quote and news.
ANIP key metrics FAQ
What is ANI Pharmaceuticals's P/E ratio?
ANI Pharmaceuticals's trailing P/E ratio is 15.6 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 7.1. At the end of fiscal 2025 it was 21.4, compared with a 10-year median of 53.4.
What is ANI Pharmaceuticals's EV/EBITDA?
ANI Pharmaceuticals's enterprise value was 8.3 times EBITDA at the end of fiscal 2025 (enterprise value $1.7 billion, EBITDA $207.3 million); the current EV/EBITDA is 7.9.
What is ANI Pharmaceuticals's return on equity?
ANI Pharmaceuticals's return on equity (ROE) was 16.2% in fiscal 2025: net income of $78.3 million on average shareholders' equity of $484.6 million.
What is ANI Pharmaceuticals's ROIC?
ANI Pharmaceuticals's return on invested capital was 9.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does ANI Pharmaceuticals have?
ANI Pharmaceuticals had total debt of $325.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.60 and $39.6 million of net debt (0.19 times EBITDA).
What is ANI Pharmaceuticals's dividend yield?
ANI Pharmaceuticals paid $1.2 million in dividends in fiscal 2025 ($0.05 per share), a payout ratio of 1.5%.
Does ANI Pharmaceuticals buy back its shares?
Yes. ANI Pharmaceuticals spent $12.2 million on net share repurchases in fiscal 2025 Shares outstanding changed +9.9% over the year, to 21.2M..
What is ANI Pharmaceuticals's free cash flow yield?
ANI Pharmaceuticals generated $150.9 million of free cash flow in fiscal 2025, a free cash flow yield of 9.0% on its market value at year-end ($1.7 billion).
What is ANI Pharmaceuticals's current ratio?
ANI Pharmaceuticals's current ratio was 2.71 at the end of fiscal 2025: current assets were 2.71 times current liabilities.